ENGTREGS Trademark

Trademark Overview


On Wednesday, July 14, 2021, a trademark application was filed for ENGTREGS with the United States Patent and Trademark Office. The USPTO has given the ENGTREGS trademark a serial number of 90828254. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Friday, December 20, 2024. This trademark is owned by GentiBio Inc.. The ENGTREGS trademark is filed in the Treatment & Processing of Materials Services, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of pharmaceuticals for others; Custom manufacturing of biological cells; consultation in the field of custom manufacture of pharmaceuticals and biological cells

Gene therapy products, namely, engineered cell platforms for immunotherapy purposes; Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders and allergic diseases and disorders

Scientific research; Pharmaceutical research; Medical research; Engineering of biological cells; genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering
engtregs

General Information


Serial Number90828254
Word MarkENGTREGS
Filing DateWednesday, July 14, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateFriday, December 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 15, 2022

Trademark Statements


Goods and ServicesCustom manufacture of pharmaceuticals for others; Custom manufacturing of biological cells; consultation in the field of custom manufacture of pharmaceuticals and biological cells
Goods and ServicesGene therapy products, namely, engineered cell platforms for immunotherapy purposes; Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders and allergic diseases and disorders
Goods and ServicesScientific research; Pharmaceutical research; Medical research; Engineering of biological cells; genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateFriday, September 17, 2021
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 17, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 17, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGentiBio Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Party NameGentiBio Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02111

Trademark Events


Event DateEvent Description
Sunday, April 3, 2022ASSIGNED TO EXAMINER
Saturday, July 17, 2021NEW APPLICATION ENTERED
Friday, September 17, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 7, 2022NON-FINAL ACTION WRITTEN
Thursday, April 7, 2022NON-FINAL ACTION E-MAILED
Thursday, April 7, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 5, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 5, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 5, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 7, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 26, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 15, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 15, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 10, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 10, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 10, 2023SOU EXTENSION 1 FILED
Monday, July 10, 2023SOU EXTENSION 1 GRANTED
Wednesday, July 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 10, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 10, 2024SOU EXTENSION 2 FILED
Wednesday, January 10, 2024SOU EXTENSION 2 GRANTED
Friday, January 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 2, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 3, 2024SOU EXTENSION 3 GRANTED
Wednesday, July 3, 2024SOU EXTENSION 3 FILED
Friday, December 20, 2024SOU TEAS EXTENSION RECEIVED
Friday, December 20, 2024SOU EXTENSION 4 FILED
Wednesday, July 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, December 21, 2024SOU EXTENSION 4 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED